The company is dedicated to enhancing the clinical efficacy of anti-cancer drugs during the pre-clinical stage in response to the high failure rate of therapeutics and the limited patient response to approved cancer treatments.
Calico Biosystems has raised €157k across 1 funding round from 1 investor, most recently a round in Jun 2024. Based in Zurich, Switzerland; active in Healthtech. Data as of 7 Aug 2026.
Timing: in window vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2024-06-25 | Other | €157k |
| Venture Kick |
| View deal → |
